Objectives: Diagnostic challenges exist for differentiating HIV dementia from Alzheimer disease (AD) in older HIV-infected (HIVϩ) individuals. Similar abnormalities in brain amyloid-␤42 (〈␤42) metabolism may be involved in HIV-associated neuropathology and AD. We evaluated the amyloid-binding agent 11 C-Pittsburgh compound B ( 11 C-PiB), a biomarker for 〈␤42 deposition, in cognitively unimpaired HIVϩ (n ϭ 10) participants and matched community controls without dementia (n ϭ 20).
with HIV. Postmortem HIVϩ subjects have increased brain A␤42 and tau deposition compared to age-matched community controls. 4 Decreased CSF 〈␤42 is observed in subjects with AD and some unimpaired community controls with fibrillar A␤42. 3 Subjects with HAND have CSF A␤42 levels similar to participants with mild AD. 1, 5 Reduced CSF 〈␤42 (Ͻ500 pg/mL) correlates with increased fibrillar amyloid deposition using the PET amyloid binding agent N-methyl-[ 11 C]2-(4-methylaminophenyl)-6hydroxybenzothiazole ( 11 C-PiB) in subjects with AD and unimpaired community controls with preclinical AD. 3 It remains unknown if a similar relationship exists for HIV. We investigated if low CSF 〈␤42 levels were predictive of increased 11 C-PiB binding potentials in cognitively unimpaired HIVϩ participants.
METHODS Participants. HIVϩ participants (n ϭ 10) (39 -59 years of age) with confirmed serologic status were selected from the CNS Highly Activated Retroviral Therapy Effects Research (CHARTER) cohort at Washington University in St. Louis (WUSTL). Four participants with low CSF 〈␤42 levels (Ͻ500 pg/mL) and 6 with normal CSF 〈␤42 levels (Ն500 pg/mL) were contacted. We selected community controls (n ϭ 20) (44 -63 years of age) of similar sex and education from memory and aging studies at the WUSTL Alzheimer's Disease Research Center (2 controls for every HIVϩ subject). We received approval from the WUSTL ethical standards committee on human experimentation for experiments using human subjects. In this case-control study, written informed consent was obtained from all subjects participating in this study. The recommendations of the Strengthening the Reporting of Observa-tional Studies in Epidemiology criteria were followed whenever applicable. 6 All participants had an 11 C-PiB scan within 2 years of concomitant lumbar puncture (LP) and neuropsychometric testing. For HIVϩ participants, cognition was assessed at the time of scan and approximately 2 years prior to LP. Cognition was evaluated in HIVϩ subjects using the previously validated global deficit score (GDS) with impairment deemed significant if GDS Ն0.5. 5 For community controls, impairment was assessed by the Clinical Dementia Rating (CDR) scale with impairment noted if CDR Ͼ0. 3 CSF evaluation. CSF collection used previously described methods. 3 CSF 〈␤42 was analyzed using a commercial enzymelinked immunosorbent assay (Innogenetics, Ghent, Belgium). Samples were kept on ice with assays performed on aliquots after a single thaw.
Imaging. Participants underwent 11 C-PiB as previously described. 7 Tracer was injected into the antecubital vein with a 60-minute 3-dimensional dynamic PET scan performed. Each subject had a T1-weighted anatomic scan with 11 C-PiB images corrected for head motion and registered to this scan. 3 The cerebellum was used as a reference as amyloid deposition has not been observed within this area in community controls. 7 Logan graphical analyses were performed and 11 C-PiB distribution volume calculated for the prefrontal, lateral temporal, precuneus, and gyrus rectus. 11 C-PiB binding potentials for each region of interest (ROI) and the mean cortical binding potential (MCBP) were calculated. 7
Statistical analysis. Statistical differences between HIVϩ and community controls for demographic and clinical values were assessed by 2 tests. Participants were divided into either low (Ͻ500 pg/mL) or normal (Ն500 pg/mL) CSF 〈␤42 groups using previously defined criterion with excellent sensitivity (100%) and good specificity (84%) for predicting subjects at risk for dementia. 8 An analysis of variance with Bonferroni correction for multiple comparisons assessed if regional differences in fibrillar amyloid plaque deposition varied with CSF 〈␤42.
RESULTS
Demographic and clinical variables were similar (table). Neither group had significant cognitive impairment. HIVϩ participants, even those with low CSF 〈␤42 (Ͻ500 pg/mL), did not have increased fibrillar amyloid plaques using 11 C-PiB ( figure 1A) . In contrast, community controls with low CSF 〈␤42 had more fibrillar amyloid plaques ( figure 1B) . Several community controls had 11 C-PiB measures indistinguishable from a typical AD pattern. 7 These unimpaired community controls may have preclinical AD. 8 We assessed the relationship between fibrillar amyloid deposition using 11 C-PiB and CSF 〈␤42 for HIVϩ participants and community controls. A 2 ϫ 2 matrix was created using CSF (〈␤42 Ͻ500 pg/mL) and 11 C-PiB MCBP (Ͻ0.18 arbitrary units) ( figure 2A ). All HIVϩ participants were located in the left upper and lower quadrants. Community controls fell within 3 boxes: left upper and lower quadrants and right lower quadrant. Half of the community controls had low CSF 〈␤42 and high Binding potentials were assessed within ROIs to determine degree of variation in fibrillar amyloid deposition. Binding potentials were elevated for community controls with low CSF 〈␤42 compared to other groups within all areas. HIVϩ participants including those with low CSF AB42 (n ϭ 4) had binding potentials similar to community controls with normal CSF 〈␤42 ( figure 2B) . DISCUSSION We observed that cognitively unimpaired HIVϩ participants, even with low CSF 〈␤42 (Ͻ500 pg/mL), did not have increased 11 C-PiB that might indicate fibrillar brain amyloid deposition.
However, community controls with a low CSF 〈␤42 were more likely to have elevated 11 C-PiB MCBP (Ͼ0.18 arbitrary units). 3 Unimpaired community controls with increased 11 C-PiB MCBP may have preclinical AD. 8 Within a 2-year retrospective interval during which we followed the HIVϩ participants, even those with low CSF 〈␤42 had no significant changes in cognition (GDS ϭ 0.18 at LP and GDS ϭ 0.31 at subsequent 11 C-PiB). Our findings suggest that 11 C-PiB MCBP differs in cognitively unimpaired HIVϩ individuals compared to community controls with low CSF 〈␤42. In the setting of HIV, low CSF 〈␤42 may not reliably predict fibrillar A␤ brain deposits as it does in preclinical AD. 9 As the HIVϩ population ages, this distinction could be diagnostically important. It remains necessary to understand whether fibrillar A␤ seen with increased 11 C-PiB is present in patients with HAND. This would assist in differentiating HAND from AD. While APOE status was not determined for participants, future studies investigating the impact of genetic risk factors on 11 C-PiB MCBP and CSF 〈␤42 in HIVϩ participants are required. 2 Both 11 C-PiB and CSF 〈␤42 levels are biomarkers of brain amyloid deposition in patients with AD and antecedent measures of impairment in community controls with preclinical AD. 8 A strong inverse correlation exists between these biomarkers. The lack of correlation between CSF 〈␤42 and 11 C-PiB MCBP in unimpaired HIVϩ participants could result from decreased A␤42 production, increased intraneuronal A␤42 deposition leading to reduced extracellular concentrations, or more extracellular A␤42 amyloid but in a diffuse, non-fibrillar A␤ form. 4, 9, 10 In each instance, relatively normal 11 C-PiB would occur. Future longitudinal examination, especially a larger sample of HIVϩ participants with low CSF A␤42 and normal 11 C-PiB, are required to understand whether observed low CSF A␤42 represents an aggregation of diffuse oligomeric forms ( 11 C-PiB-negative) that eventually become substantial fibrillar ( 11 C-PiB-positive) deposits, 1,5 or simply the low normal end of CSF A␤42 in HIVϩ participants. 9 Our findings reinforce the importance of understanding amyloid metabolism in HIV-associated neuropathology, while confirming that low CSF 〈␤42 is not simply a manifestation of early fibrillar A␤ deposition in the brain.
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